Wiktoria Wdowiak

Wiktoria Wdowiak

Auto-generated profile, based on publicly available information

Wiktoria Wdowiak

Wroclaw Medical University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2026 in Health Problems of Civilization
Verified
Journal Article
Open access
PDF file
RWRafał Wilczyński
Rafał Wilczyński
WWWiktoria Wdowiak
Wiktoria Wdowiak
WWWeronika Wrona
Weronika Wrona
JOJulia Owsik
Julia Owsik
HLHanna Ludwisiak
Hanna Ludwisiak
MDMałgorzata Dorożalska
Małgorzata Dorożalska
Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in athletes are rare but catastrophic events that generate substantial medical, ethical, and public health concern. Although regular physical activity is associated with significant cardiovascular benefits, intense training and competition may unmask underlying structural or electrical heart diseases in susceptible individuals. The most common causes of SCA and SCD in young athletes include hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, left ventricular hypertrophy, myocarditis, congenital coronary artery anomalies, and primary electrical disorders such as long QT syndrome. In athletes over 35 years of age, asymptomatic atherosclerotic cardiovascular disease predominates. Pre-participation cardiovascular screening, including medical history, physical examination, and, in some regions, electrocardiography (ECG) aims to identify individuals at risk. However, controversy persists regarding the sensitivity, specificity, cost-effectiveness, and potential for false-positive findings associated with screening strategies. Rapid recognition of SCA, immediate cardiopulmonary resuscitation, and early defibrillation with automated external defibrillators (AEDs) remain critical determinants of survival. The aim of this review is to summarize current evidence on the epidemiology, risk stratification, screening strategies, and emergency management of SCA and SCD in athletes and to highlight ongoing challenges and areas for future research.

8 July 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
SWSzymon Wróbel
Szymon Wróbel
KWKamil Andrzej Wiązania
Kamil Andrzej Wiązania
RWRafał Wilczyński
Rafał Wilczyński
WWWeronika Wrona
Weronika Wrona
MDMałgorzata Dorożalska
Małgorzata Dorożalska
HLHanna Ludwisiak
Hanna Ludwisiak
Background. With the continuous development of new technologies, especially digital technologies, the possibilities provided by telehealth continue to increase. Research shows that the use of telehealth tools can be successfully used for managing patients with chronic conditions. Aim. As the number of chronic conditions within the world’s population rises, their effect becomes evident in terms of lowering patients’ quality of life and life expectancy. Telehealth can be an effective solution to this growing problem. This review is intended to examine the state-of-the-art studies in relation to the effect of telehealth on chronic disorder management, focusing mainly on clinical outcomes, quality of life, and healthcare costs. Material and methods. We reviewed the available scientific literature in databases such as PubMed, Scopus, and Web of Science. We included original research studies, systematic reviews, and meta-analyses that examined the impact of telehealth technologies on the management of patients with chronic diseases and were published in Polish or English between January 2020 and May 2026. Results. From the cited literature, it is clear that the use of telehealth has shown effectiveness in managing chronic disease. Although positive results can be observed in the short-term control of diseases such as hypertension, heart failure, diabetes, asthma, and chronic obstructive pulmonary disease, the effects of long-term management are unknown. Conclusions. This narrative review provides important insights regarding both the possible benefits and constraints of telehealth when managing chronic diseases. With the increasing use of telemedicine, it is vital to consider such difficulties and make sure that telehealth is accessible and efficient for all chronic patients.

2 October 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
WWWeronika Wrona
Weronika Wrona
MDMałgorzata Dorożalska
Małgorzata Dorożalska
HLHanna Ludwisiak
Hanna Ludwisiak
WWWiktoria Wdowiak
Wiktoria Wdowiak
JOJulia Owsik
Julia Owsik
AWAnna Wojdas
Anna Wojdas
Background: Haemodialysis imposes substantial treatment burden, affecting medication adherence and health-related quality of life (HRQoL). This study assessed treatment burden and its associations with these outcomes in adults receiving haemodialysis. Aim: To assess treatment burden in adults with end-stage renal disease (ESRD) receiving haemodialysis and examine its associations with medication adherence and HRQoL. Materials and Methods: A systematic search of PubMed, Embase and Scopus was conducted for publications from 2000 to 2026. After deduplication of 290 records, manual screening yielded 37 eligible studies — restricted to systematic reviews, meta-analyses, clinical trials, and Mendelian randomisation analyses involving adults (≥18 years). Results: Treatment burden in haemodialysis patients is multidimensional, encompassing high pill burden, time demands and significant psychological distress. Non-adherence rates reached up to 50%, driven by regimen complexity, depression, and caregiver strain. Physical HRQoL was more severely impaired than mental HRQoL, with fatigue and musculoskeletal symptoms as primary drivers. Longer dialysis vintage correlated with progressive symptom worsening Conclusions: Treatment burden in ESRD patients undergoing haemodialysis significantly impairs medication adherence and HRQoL, particularly in physical domains. Integrated, patient-centred strategies, including regimen simplification and psychosocial support, are needed.

2 October 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
WWWeronika Wrona
Weronika Wrona
AWAnna Wojdas
Anna Wojdas
WWWiktoria Wdowiak
Wiktoria Wdowiak
MDMałgorzata Dorożalska
Małgorzata Dorożalska
MJMałgorzata Jurczyk
Małgorzata Jurczyk
WRWeronika Ryś
Weronika Ryś
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are primarily used in type 2 diabetes and obesity. Evidence suggests additional cardiovascular, renal, and neurological effects, with important socioeconomic implications. Aim: To evaluate GLP-1 RA effects beyond metabolic control, focusing on cardiovascular, renal, neurological, physical activity, and socioeconomic outcomes. Material and methods: PubMed, Embase, and Scopus were searched for studies published from 2022 to 2026. Adult human studies assessing cardiovascular, renal, cerebrovascular, neurological or socioeconomic outcomes were included. After screening, 39 publications were qualitatively synthesized. Results: GLP-1 RAs were associated with reduced major adverse cardiovascular events, cardiovascular mortality, myocardial infarction, and selected heart-failure outcomes. Semaglutide reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease. Neurological effects included reduced cerebrovascular events and intracranial pressure, while evidence regarding cognition and neurodegenerative disorders remained heterogeneous. Conclusions: GLP-1 RAs exert multisystem effects beyond metabolic control, including cardiovascular and renal protection and neurological effects. Their expanding use may provide substantial health benefits but also raises concerns regarding treatment costs and socioeconomic disparities in access.

2 October 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
MDMałgorzata Dorożalska
Małgorzata Dorożalska
MJMałgorzata Jurczyk
Małgorzata Jurczyk
AGAleksandra Glapa
Aleksandra Glapa
WWWeronika Wrona
Weronika Wrona
WWWiktoria Wdowiak
Wiktoria Wdowiak
WRWeronika Ryś
Weronika Ryś
Background. Prediabetes elevates lifetime risk of type 2 diabetes and cardiovascular disease. Moderate-intensity continuous training (MICT) improves metabolic health but is limited by time demands. High-intensity interval training (HIIT) is a time-efficient alternative that can match or exceed MICT benefits for insulin sensitivity and glycemic control, yet optimal protocols remain unclear. Aim. To evaluate the effects of HIIT on insulin sensitivity and metabolic health in adults with prediabetes. Material and methods. PubMed, Scopus and Google Scholar were searched for English-language peer-reviewed studies (2015–2026) on HIIT and insulin sensitivity or metabolic outcomes in adults with prediabetes. Eligible randomised controlled trials, controlled trials, observational studies and reviews were screened by title/abstract and full text after duplicate removal; reference lists were also hand-searched. Results. HIIT improved muscle and whole-body insulin sensitivity, reduced fasting glucose and HbA1c, and increased VO₂max, often comparably to MICT despite lower time commitment. Higher-volume protocols yielded greater HbA1c reductions; greater volume also strengthened benefits for fasting glucose, insulin and HOMA-IR. Combined HIIT plus diet produced the best BMI outcomes, while clamp-derived insulin sensitivity improvements partly depended on ≥3 % weight loss. Superiority over MICT varied by outcome and protocol. Conclusions. HIIT delivers meaningful gains in insulin sensitivity and metabolic health that are frequently comparable to MICT with substantially less time. Larger standardised trials are needed to define optimal, individualised prescriptions for type 2 diabetes prevention.

23 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
WŁWiktoria Łuniewska
Wiktoria Łuniewska
AMAgata Mytych
Agata Mytych
JJJulia Jackowska
Julia Jackowska
WWWeronika Wrona
Weronika Wrona
WWWiktoria Wdowiak
Wiktoria Wdowiak
The HeartMate 3 (HM3) left ventricular assist device (LVAD) has become the current standard for mechanical circulatory support in patients with advanced heart failure. Its innovative design, including a fully magnetically levitated rotor and artificial pulse generation, has improved hemocompatibility and reduced mechanical failures. However, device-related complications remain a significant concern affecting patient outcomes. The main side effects of HM3 implantation, such as bleeding, infections, neurological events, and pump thrombosis, are examined in this review along with how they affect survival. Data from major clinical trials and observational studies were examined to identify complication rates, risk factors, and trends over time. Bleeding is the most frequent adverse event, occurring in approximately one-third of patients, with gastrointestinal bleeding observed in nearly 10%. 23–30% of recipients experience infections, especially driveline infections, and 3–5% experience neurological problems like ischaemic and hemorrhagic stroke, usually in the first six months following implantation. Pump thrombosis rates with HM3 remain among the lowest reported, ranging from 1.4% at two years to 2.8% at five years. Long-term results are positive in spite of these difficulties, with survival rates surpassing 80% at two years and 58% at five. Continued refinement of device technology and patient management is essential to further reduce complications and improve overall survival and quality of life.